JQ1 treatment reduced the engraftment of human CML CD45+ cells(Fig. 7H, I) and spleen (Fig. 7J) at 12 weeks after transplantation, and sensitized imatinib effect. The gene discussed is PTPRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.